Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shugo Yajima

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Clinical Nutrition (Edinburgh, Scotland)|July 21, 2023
The significance of SARC-F scores in predicting postoperative outcomes of older adults undergoing elective major surgery for urologic cancerShugo Yajima, Hiroshi Fukushima, Shioto Oda, et al.
Japanese Journal of Clinical Oncology|October 29, 2025
Bayesian reanalysis of avelumab maintenance therapy in Asian and Japanese patients with advanced urothelial carcinoma: evidence from the JAVELIN Bladder 100 trialShugo Yajima, Soichiro Yoshida, Wei Chen, et al.
European Urology Open Science|February 16, 2026
Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysisShugo Yajima, Wei Chen, Kohei Hirose, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 18, 2026
Bayesian Multi-Criteria Decision Analysis of Net Clinical Benefit in ARASENS: Overall and Japanese Subgroup ResultsKenji Tanabe, Soichiro Yoshida, Wei Chen, et al.
Urologic Oncology|January 22, 2026
Pharmacologic synergy versus independent action in androgen receptor-axis-targeted agent-docetaxel triplet therapy for metastatic hormone-sensitive prostate cancer: a copula-based analysisWei Chen, Soichiro Yoshida, Shugo Yajima, et al.
Anticancer Research|June 29, 2026
Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell CarcinomaMotohiro Fujiwara, Soichiro Yoshida, Shugo Yajima, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 23, 2025
Risk factors for rectal wall infiltration in hydrogel spacer placement: Influence of biopsy approachKohei Hirose, Yasukazu Nakanishi, Ryo Andy Ogasawara, et al.
Clinical Genitourinary Cancer|May 18, 2026
Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event ReanalysisMotohiro Fujiwara, Soichiro Yoshida, Shugo Yajima, et al.
Urology|December 26, 2022
Deep Learning-Based Seminal Vesicle and Vas Deferens Recognition in the Posterior Approach of Robot-Assisted Radical ProstatectomyNobushige Takeshita, Shinichi Sakamoto, Daichi Kitaguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 21, 2020
Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancerHajime Tanaka, Hiroshi Fukushima, Toshiki Kijima, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Clinical Nutrition (Edinburgh, Scotland)|July 21, 2023
The significance of SARC-F scores in predicting postoperative outcomes of older adults undergoing elective major surgery for urologic cancerShugo Yajima, Hiroshi Fukushima, Shioto Oda, et al.
Japanese Journal of Clinical Oncology|October 29, 2025
Bayesian reanalysis of avelumab maintenance therapy in Asian and Japanese patients with advanced urothelial carcinoma: evidence from the JAVELIN Bladder 100 trialShugo Yajima, Soichiro Yoshida, Wei Chen, et al.
European Urology Open Science|February 16, 2026
Re-evaluating Treatments for Advanced Urothelial Carcinoma Using Restricted Mean Survival Time: A Systematic Review and Network Meta-analysisShugo Yajima, Wei Chen, Kohei Hirose, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 18, 2026
Bayesian Multi-Criteria Decision Analysis of Net Clinical Benefit in ARASENS: Overall and Japanese Subgroup ResultsKenji Tanabe, Soichiro Yoshida, Wei Chen, et al.
Urologic Oncology|January 22, 2026
Pharmacologic synergy versus independent action in androgen receptor-axis-targeted agent-docetaxel triplet therapy for metastatic hormone-sensitive prostate cancer: a copula-based analysisWei Chen, Soichiro Yoshida, Shugo Yajima, et al.
Anticancer Research|June 29, 2026
Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell CarcinomaMotohiro Fujiwara, Soichiro Yoshida, Shugo Yajima, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 23, 2025
Risk factors for rectal wall infiltration in hydrogel spacer placement: Influence of biopsy approachKohei Hirose, Yasukazu Nakanishi, Ryo Andy Ogasawara, et al.
Clinical Genitourinary Cancer|May 18, 2026
Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event ReanalysisMotohiro Fujiwara, Soichiro Yoshida, Shugo Yajima, et al.
Urology|December 26, 2022
Deep Learning-Based Seminal Vesicle and Vas Deferens Recognition in the Posterior Approach of Robot-Assisted Radical ProstatectomyNobushige Takeshita, Shinichi Sakamoto, Daichi Kitaguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 21, 2020
Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancerHajime Tanaka, Hiroshi Fukushima, Toshiki Kijima, et al.
Pageof 11